Biogen waves bye to $217m ALS partnership with Karyopharm

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $

Karyopharm drug tested in ‘industry-first’ approach to brain...

FDA clears Karyopharm’s myeloma drug despite advisory panel ...

Advisers urge FDA to delay decision on Karyopharm cancer dru...

Advisers to the US drugs regulator have said a decision on whether to approve Karyopharm’s multiple myeloma combination should be delayed until the results of a phase 3 trial, due late this